Innovative Vaccine Approaches | EK50

Study of SARS-CoV-2 adjuvanted by OMVs as a vaccine platform and future perspectives

Preview Available

Study of SARS-CoV-2 adjuvanted by OMVs as a vaccine platform and future perspectives

• Amanda I. Portilho, Other, Adolfo Lutz Institute, University of São Paulo

Novel Bile Salt Stabilized Nano-Colloidal Carriers For Oral Vaccine Delivery

Preview Available

Novel Bile Salt Stabilized Nano-Colloidal Carriers For Oral Vaccine Delivery

• Anshuman Shukla, PhD, Panjab University, Chandigarh, India

Stabilization of the SARS-CoV-2 Spike receptor-binding domain using deep mutational scanning and structure-based design

Preview Available

Stabilization of the SARS-CoV-2 Spike receptor-binding domain using deep mutational scanning and structure-based design

• Daniel Ellis, PhD, University of Washington

Moving beyond the titer paradigm: rational design of a next-gen glycoconjugate vaccine inducing highly functional antibodies

Preview Available

Moving beyond the titer paradigm: rational design of a next-gen glycoconjugate vaccine inducing highly functional antibodies

• Giuseppe Stefanetti, PhD, Harvard Medical School

First recombinant dual-hit glycoconjugate vaccine production platform to combat Group A Streptococcus

Preview Available

First recombinant dual-hit glycoconjugate vaccine production platform to combat Group A Streptococcus

• Helge C. Dorfmueller, PhD, University of Dundee

Vaccine nanoparticles for elicitation of strong cellular and humoral immune responses.

Preview Available

Vaccine nanoparticles for elicitation of strong cellular and humoral immune responses.

• James J. Moon, PhD, University of Michigan, Ann Arbor

Using synthetic biology to generate rapidly manufacturable hyper-stable vaccines

Preview Available

Using synthetic biology to generate rapidly manufacturable hyper-stable vaccines

• John J. Miles, PhD, James Cook University

Design and immunogenicity of a Pan-SARS-CoV-2 synthetic DNA vaccine

Preview Available

Design and immunogenicity of a Pan-SARS-CoV-2 synthetic DNA vaccine

• Katherine Schultheis, MSc, Inovio Pharmaceuticals

Epitope identification of SARS-CoV-2 structural proteins using in silico approaches to obtain conserved rational immunogenic peptide

Preview Available

Epitope identification of SARS-CoV-2 structural proteins using in silico approaches to obtain conserved rational immunogenic peptide

• Leonardo A. de Almeida, PhD, Universidade Federal de Alfenas

Potent neutralizing humoral and cellular responses induced by SARS-CoV-2 Spike protein – polymeric glyco-adjuvant conjugate

Preview Available

Potent neutralizing humoral and cellular responses induced by SARS-CoV-2 Spike protein – polymeric glyco-adjuvant conjugate

• Michal M. Raczy, MS, University of Chicago